caa a22 4500 469090669 CHVBK 20180323133016.0 cr unu---uuuuu 170328e19920601xx s 000 0 eng 10.1007/BF00464709 doi (NATIONALLICENCE)springer-10.1007/BF00464709 Elkon Keith The Hospital for Special Surgery-Cornell University Medical College, 10021, New York, NY, USA aut Use of synthetic peptides for the detection and quantification of autoantibodies [Elektronische Daten] [Keith Elkon] Summary and conclusions: The rapid progress made over the last 10 years in the identification of individual autoantigens and in the localization of the epitopes involved, has resulted in a parallel reduction in the complexity of the antigen required for the detection of autoantibodies. The ability to use synthetic peptides as antigens is a remarkable culmination of this process considering that many antigenic particles contain multiple proteins (eg. Sm consist of 8 or more individual proteins). Despite the fact that patients with SLE have a polyclonal hypergammaglobulinemia, excellent correlations between ELISAs utilizing the P2 or SmB/B′ synthetic peptides, ELISAs utilizing r proteins and immunoblotting were obtained [28, 38, 50]. However, false positive/non-specific binding to a P2-BSA-glutaraldehyde conjugate has been observed with serum from old MRL/lpr mice (unpublished observations). In addition, some of the results obtained in human autoimmune diseases suggest that non-specific binding may be problematic in some instances. It is difficult, at present, to know whether the higher frequencies of detection of autoantibodies to certain synthetic peptide antigens reflect increased sensitivity or decreased specificity. Synthetic peptide antigens have beeen used to detect autoantibodies in both organ specific and multisystem autoimmune diseases. In only a small number of cases have these reagents been rigorously tested for sensitivity and specificity. Despite this, synthetic peptides have been shown to be valuable for detection and quantification of autoantibodies in certain clinical situations. Undoubtedly, further progress in epitope mapping of autoantigens coupled with technological advances in protein synthesis and improved prediction of protein structure will lead to a large number of synthetic peptide antigens for research and clinical applications. It is unlikely that short synthetic peptides will substitute for native proteins in all instances since some autoantibodies show a striking preference for conformational epitopes. Kluwer Academic Publishers, 1992 autoantibody nationallicence autoantigen nationallicence synthetic peptide nationallicence r : recombinant nationallicence SLE : systemic lupus erythematosus nationallicence Molecular Biology Reports Kluwer Academic Publishers 16/3(1992-06-01), 207-212 0301-4851 16:3<207 1992 16 11033 https://doi.org/10.1007/BF00464709 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00464709 text/html Onlinezugriff via DOI NATIONALLICENCE 100 1- Elkon Keith The Hospital for Special Surgery-Cornell University Medical College, 10021, New York, NY, USA aut NATIONALLICENCE 773 0- Molecular Biology Reports Kluwer Academic Publishers 16/3(1992-06-01), 207-212 0301-4851 16:3<207 1992 16 11033 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer